ATRC · AtriCure, Inc.
$44.30
+0.81 (+1.86%)
At close · Aug 14
Market Cap
$2.26B
Shares
50.87M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$44.30
Open$43.71
Day$43.22–44.48
52W close$25.86–44.30
Avg vol 30d839K
Short int3.9M · 7.6% float · 3.7d
Short vol62%
Last earningsJul 23, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 27
Up next
Next earnings call
Oct 17, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 27, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+31%
above
RSI (14)
77
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+39%
trailing
YTD return
+12%
this year
Relative strength
+26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Falling
7.60% of float · ▼ -20.6% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
251 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
Gross margin
199%
contracting
EPS growth
+75%
Y/Y
Free cash flow
$48.3M
Valuation
P/E 211.5
rich
Balance sheet
$98.9M
net cash
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Worldwide revenue
· Full year 2026
$602M – $610M
Adjusted EBITDA
· Full year 2026
$85M – $89M
Adjusted earnings per share
· Full year 2026
$0.24 – $0.32
Net income per share
· Full year 2026
$0.05 – $0.13
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2024
Revenue
· 2025
$517M – $527M
Adjusted EBITDA
· full year 2025
$42M – $44M
Guided vs delivered
· last 1 settled
Revenue
full year 2024
guided $459M – $466M
$465.31M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+31%
Bullish
RSI (14)
77
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Golden cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Falling
7.60% of float · ▼ -20.6% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
251 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26
Now $44 · 100%
Range high $44
vs 200-day avg +33%
vs 50-day avg +31%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $27.3M | second quarter 2026 | — |
|
|
|||
| Adjusted income (loss) per share non-GAAP | $0.06 | Q4 2025 | — |
| Adjusted loss per share non-GAAP | -$0.11 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRC
this stock
AtriCure, Inc.
|
$2.26B | +12.0% | +15.4% | 211.5 | 7.6% |
|
ISRG
Intuitive Surgical Inc
|
$139.37B | -30.3% | +20.5% | 45.3 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.99B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.97B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRC | +7.0% | +26.8% | +39.4% | +17.3% | +12.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +6.6% | +22.3% | +25.6% | +13.4% | -1.9% |
Key facts
CIK
1323885
CUSIP
04963C209
13F (30d)
244 filings
242 filers
Visit website
Investor relations